BILLERICA, Mass., Sept. 4, 2012 /PRNewswire/ -- Aushon BioSystems today announced that Martin Verhoef has been appointed Chief Executive Officer. Mr. Verhoef has also been appointed to the Company's Board of Directors. Peter Honkanen, Founder and former Chief Executive Officer, will assume the Chief Operating Officer role and continue as a Board Director.
"We welcome Martin to Aushon and are especially excited about the extensive commercialization experience he brings to the organization. Now that the company has achieved its product development milestones, it's sharpening its focus on the commercialization of its products. With his background and experience, Martin offers the right leadership to realize the company's potential," commented Rich D'Amore, Founding Partner of North Bridge Venture Partners.
"I'm very excited to work with Martin and to shift my focus to further strengthening the Development and Operations teams as we prepare the organization for substantial growth," added Peter Honkanen.
Mr. Verhoef has a career of over 25 years experience in the life science research tools and molecular diagnostics business. Prior to joining Aushon, Mr. Verhoef was Chief Executive Officer at the molecular diagnostic firms MiraDx and PrimeraDx. He was also a member of Ciphergen's executive team where he led the company's BioSystems Division. Mr. Verhoef has also held various senior management roles at Agilent in Germany and the US. He holds BS degrees in Medical Chemistry and Chemistry from the van 't Hoff Institute in Rotterdam, The Netherlands.
"I am delighted to be joining Aushon at this stage of its development. The new Cira™ platform has been exceptionally well received and is already being adopted by key customers throughout the life science industry. I strongly believe that CiraPlex™ will become the platform of choice for protein biomarker analysis and will help drive personalized medicine," commented Mr. Verhoef.
Aushon BioSystems, Inc., provides a comprehensive suite of multiplex immunoassay products and services for protein biomarker discovery, development, and analysis to leading pharmaceutical, biotechnology, academic, and diagnostic clients worldwide. Our unique combination of proprietary microarray printing, extensive biomarker content, and our innovative Cira immunoassay platform deliver exceptional performance, quality, and reliability to accelerate preclinical and clinical biomarker research. Our customers, who include nine of the top ten pharmaceutical companies, trust Aushon to supply the most reliable biomarker data available, lowering costs and improving research productivity.
Vice President, Sales & Marketing
|SOURCE Aushon BioSystems|
Copyright©2012 PR Newswire.
All rights reserved